1. Batches of Sabril (vigabatrin) recalled due to tiapride contamination

   News item 29 July 2023 Pages: 1 - 1

2. Initiation of opioids increase risk of death in older adults with dementia

   News item 29 July 2023 Pages: 2 - 2

3. Statin labelling updated with risk of myasthenia gravis

   News item 29 July 2023 Pages: 3 - 3

4. ADR-related hospitalisations and in-hospital deaths

   Epidemiology clinical study 29 July 2023 Pages: 4 - 4

5. Androgen receptor pathway inhibitor-related MACE

   Clinical study 29 July 2023 Pages: 5 - 5

6. Faecal microbiota transplantation "safe, well tolerated" in recurrent C. difficile infection

   Clinical study 29 July 2023 Pages: 6 - 6

7. Herpes zoster vaccine live: no increase in serious AEs

   Epidemiology clinical study 29 July 2023 Pages: 7 - 7

8. Multikinase inhibitor-related psychiatric AEs

   Clinical study 29 July 2023 Pages: 8 - 8

9. NSAID cardiovascular risk in diabetic patients not impacted by HbA1c level

   Clinical study 29 July 2023 Pages: 9 - 9

10. Uncontrolled BP despite antihypertensives increases risk of MACE and ESRD

    Clinical study 29 July 2023 Pages: 10 - 10

11. Zoledronic acid-related osteonecrosis of the jaw

    Clinical study 29 July 2023 Pages: 11 - 11

12. Other adverse reaction research

    News item 29 July 2023 Pages: 12 - 12

13. Abiraterone acetate/prednisone misuse

    Case report 29 July 2023 Pages: 13 - 13

14. Abiraterone/potassium-chloride

    Case report 29 July 2023 Pages: 14 - 14

15. Acetazolamide/antiglaucomas/dexamethasone

    Case report 29 July 2023 Pages: 15 - 15

16. Adalimumab

    Case report 29 July 2023 Pages: 16 - 16

17. Adalimumab

    Case report 29 July 2023 Pages: 17 - 17

18. Adalimumab

    Case report 29 July 2023 Pages: 18 - 18

19. Adalimumab

    Case report 29 July 2023 Pages: 19 - 19

20. Adalimumab/estradiol valerate/ixekizumab

    Case report 29 July 2023 Pages: 20 - 20

21. Adalimumab/guselkumab/secukinumab

    Case report 29 July 2023 Pages: 21 - 21

22. Adalimumab/secukinumab

    Case report 29 July 2023 Pages: 22 - 22

23. Adalimumab/tocilizumab

    Case report 29 July 2023 Pages: 23 - 23

24. Albumins/furosemide

    Case report 29 July 2023 Pages: 24 - 24

25. Alectinib/crizotinib/nivolumab

    Case report 29 July 2023 Pages: 25 - 25

26. Alemtuzumab

    Case report 29 July 2023 Pages: 26 - 26

27. Alteplase

    Case report 29 July 2023 Pages: 27 - 27

28. Amiodarone

    Case report 29 July 2023 Pages: 28 - 28

29. Amiodarone/lidocaine/metoprolol

    Case report 29 July 2023 Pages: 29 - 29

30. Amoxicillin

    Case report 29 July 2023 Pages: 30 - 30

31. Amphotericin-B

    Case report 29 July 2023 Pages: 31 - 31

32. Anakinra/onasemnogene abeparvovec

    Case report 29 July 2023 Pages: 32 - 32

33. Anti-inflammatories

    Case report 29 July 2023 Pages: 33 - 33

34. Antiarrhythmics

    Case report 29 July 2023 Pages: 34 - 34

35. Antibacterials/methylprednisolone

    Case report 29 July 2023 Pages: 35 - 35

36. Antibacterials/potassium-chloride

    Case report 29 July 2023 Pages: 36 - 36

37. Antibacterials/warfarin

    Case report 29 July 2023 Pages: 37 - 37

38. Antidepressants/asenapine/valproate-semisodium

    Case report 29 July 2023 Pages: 38 - 38

39. Antiepileptic-drugs

    Case report 29 July 2023 Pages: 39 - 39

40. Antifungals/levofloxacin/pranoprofen

    Case report 29 July 2023 Pages: 40 - 40

41. Antimalarials/paracetamol

    Case report 29 July 2023 Pages: 41 - 41

42. Antineoplastics

    Case report 29 July 2023 Pages: 42 - 42

43. Antineoplastics

    Case report 29 July 2023 Pages: 43 - 43

44. Antineoplastics

    Case report 29 July 2023 Pages: 44 - 44

45. Antineoplastics

    Case report 29 July 2023 Pages: 45 - 45

46. Antineoplastics

    Case report 29 July 2023 Pages: 46 - 46

47. Antineoplastics

    Case report 29 July 2023 Pages: 47 - 47

48. Antineoplastics

    Case report 29 July 2023 Pages: 48 - 48

49. Antineoplastics

    Case report 29 July 2023 Pages: 49 - 49

50. Antineoplastics

    Case report 29 July 2023 Pages: 50 - 50